天津發展(00882.HK)斥1.4億人幣購中成藥生產製造平臺
天津發展(00882.HK)公佈,其間接非全資附屬力生製藥擬以代價約1.37億元人民幣(約1.51億港元),收購江西青春康源製藥的65%股權。
江西青春康源主要從事中藥製劑及中藥提取物研發、生產及銷售,產品覆蓋消化系統、呼吸系統、骨骼肌肉及全身抗感染等多個醫藥領域。
公司指,江西青春康源將成爲其中成藥生產製造平臺,有助增強產業鏈韌性及提升公司在中成藥市場的佔有率。公司將可藉助江西青春康源的B2B電子商貿平臺,積極開拓電子商貿業務,從而擴大銷售網絡,達至品牌價值最大化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.